Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) - PubMed
4 hours ago
- #Brain metastases
- #Triple-negative breast cancer
- #Immunotherapy
- Phase II clinical study evaluates adebrelimab, bevacizumab, and cisplatin/carboplatin in triple-negative breast cancer (TNBC) patients with brain metastases (BMs).
- Primary endpoint was CNS objective response rate (CNS-ORR) of 77.1%, with a clinical benefit rate (CNS-CBR) of 80.0%.
- Median progression-free survival (PFS) was 8.3 months, CNS-PFS was 10.3 months, and overall survival (OS) was 21.1 months.
- Progression was intracranial-only in 32.1%, extracranial-only in 35.7%, and both in 32.1% of patients.
- Grade ≥3 treatment-related adverse events occurred in 65.7% of patients, with serious adverse events in 14.3% and no treatment-related deaths.
- The combination therapy showed promising intracranial antitumor activity and manageable safety, warranting further investigation.